138.99 USD
↘ 3.10 (2.18%)AT CLOSE (11:59 AM EDT)
Gilead Sciences Inc
GILDNASDAQ • USD
139.03
↗ 0.40 (0.28%)
POST MARKET (AS OF 06:08 PM EDT)
Post Market
AS OF 06:08 PM EDT
139.03
↗ 0.40 (0.28%)
Market: OPEN
Open?$142.38
High?$142.38
Low?$138.45
Prev. Close?$142.09
Volume?4.4M
Avg. Volume?6.3M
VWAP?$139.84
Rel. Volume?0.70x
Bid / Ask
Bid?$132.08 × 100
Ask?$147.68 × 100
Spread?$15.60
Midpoint?$139.88
Valuation & Ratios
Market Cap?176.4B
Shares Out?1.2B
Float?1.2B
Float %?99.7%
P/E Ratio?20.72
P/B Ratio?7.77
EPS?$6.86
Dividend?2.27%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.55Adequate
Quick Ratio?1.40Adequate
Cash Ratio?0.64Adequate
Debt/Equity?1.10Moderate
ValuationFAIRLY VALUED
Score67/100
P/E?20.7FAIR▾
P/B?7.77FAIR▾
P/S?5.99FAIR▾
P/FCF?18.7CHEAP▾
EV/EBITDA?13.5FAIR▾
EV/Sales?6.58HIGH▾
Returns & Efficiency
ROE?37.5%STRONG▾
ROA?14.4%STRONG▾
Cash Flow & Enterprise
FCF?$9.5B
Enterprise Value?$193.7B
Related Companies
Loading...
News
Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees
17.0K
Market Cap
176.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1992-01-22
Address
333 LAKESIDE DR
FOSTER CITY, CA 94404
Phone: (650) 574-3000
FOSTER CITY, CA 94404
Phone: (650) 574-3000